A scientific enigma, dormant for nearly a quarter-century, has been unraveled by a team of researchers. Delving into the intricacies of cellular behavior, the investigators meticulously followed a trail of evidence that led them from fruit flies to mice and, ultimately, to humans. The revelation points to cannibalistic cells as the likely culprits behind a rare form of human immunodeficiency, bringing closure to a long-standing mystery.
The implications of this discovery extend beyond understanding a peculiar medical condition. The newfound knowledge holds the promise of enhancing emerging cancer treatment methods, marking a crucial milestone in medical research.
Denise Montell from UC Santa Barbara, expressing her enthusiasm, remarked, “This paper takes us from very fundamental cell biology in a fly, to explaining a human disease and harnessing that knowledge for a cancer therapy.” The profound significance of this achievement lies not only in the breadth of its scope, encompassing diverse organisms and medical conditions, but also in the seamless integration of these discoveries into a unified narrative.
The research findings, recently published in the Proceedings of the National Academy of Sciences, represent a comprehensive exploration that transcends traditional boundaries. Now, the scientific community eagerly awaits further insights as the researchers from Montell’s lab delve into unraveling the mechanisms and implications underlying this groundbreaking discovery.
A time-honored genetic sequence
At the heart of this narrative is the gene Rac2 and the pivotal protein it encodes. Within the realm of human genetics, Rac2 stands as one of three Rac genes, and its evolutionary antiquity suggests a fundamental role in biological functions, as emphasized by senior author Montell, Duggan Professor, and Distinguished Professor of Molecular, Cellular, and Developmental Biology.
The key function of Rac proteins lies in their role in constructing a cell’s cytoskeleton—the dynamic scaffolding that enables cells to maintain their shape or undergo deformation as needed. Professor Montell’s earlier work in 1996, focused on a small group of cells within the fruit fly ovary, unveiled the significance of Rac proteins in cellular movement. Since then, Rac‘s influence as a nearly universal regulator of cell motility in animal cells has become apparent, underscoring its essential role in cellular dynamics.
During her pioneering work in the 1990s, Professor Montell made a curious observation involving a hyperactive form of the Rac1 protein. When expressed in a limited number of cells within a fly’s egg chamber, this hyperactive Rac1 led to the demise of the entire tissue, composed of approximately 900 cells. Lead author Abhinava Mishra, a project scientist in Montell’s lab, further elucidates this phenomenon, emphasizing the destructive potential of expressing active Rac in a confined cellular context. This revelation not only adds a fascinating layer to our understanding of Rac proteins but also underscores the delicate balance that governs cellular tissues in their intricate dance of regulation and response.
Unlocking the mysteries behind a scientific enigma that persisted for a quarter-century, Professor Montell expressed the satisfaction of resolving their “25-year-old cold case.” The investigation took a pivotal turn as evidence mounted, pointing towards a phenomenon known as cell eating or cannibalism, implicating it in the destructive process observed in tissue.
A significant revelation emerged from the study of normal fly egg development, where certain cells akin to border cells engage in cellular cannibalism by consuming neighboring cells that are no longer needed. This, however, is not an isolated occurrence, as millions of old red blood cells are similarly eliminated from the human body through this process every second.
In the context of their study, the focus shifted to Rac2, a key player in the intricate cellular eating process. Rac, in its normal role, facilitates the engulfment of target cells by the consuming cell. The research team explored the hypothesis that a hyperactive form of Rac2 might be triggering premature consumption of neighboring cells by the border cells.
To actualize this premature consumption, the border cells require the ability to recognize their targets, a process dependent on a specific receptor. Significantly, when lead author Abhinava Mishra blocked this receptor, the border cells expressing activated Rac2 ceased their consumption of neighbors, leading to the preservation of the egg chamber’s vitality.
The satisfaction of solving this decades-old puzzle was palpable for Professor Montell, who exclaimed, “Our 25-year-old cold case was solved, and that was very satisfying for us.” While acknowledging the niche focus on Drosophila egg development, the broader implications of this discovery loomed on the horizon, promising to extend the understanding of cellular dynamics and potentially impacting areas beyond this specific realm of study.
Enigmatic immune phenomenon
Around the time of their groundbreaking discovery, Professor Montell’s lab stumbled upon a compelling study in the journal Blood that added an intriguing layer to their research. The study highlighted a shared mutation in three unrelated individuals experiencing recurrent infections, all of whom possessed an identical hyperactivating mutation in Rac2—a Rac protein primarily produced in blood cells. This discovery resonated with the recent revelations in fruit flies, prompting Professor Montell to explore potential connections.
Despite the mild activation level of the patients’ mutation, it had severe consequences, leading to recurrent infections and necessitating bone marrow transplants. Blood tests unveiled a strikingly low count of T cells, specialized white blood cells pivotal to the immune system, in these patients. To delve deeper into the mystery, the team at the National Institutes of Health introduced the Rac2 mutation into mice, reproducing the unexplained T cell loss observed in humans. Intriguingly, the T cells with hyperactive Rac developed normally in the mice’s bone marrow, migrated to the thymus, and continued maturing without any issues. However, an unexplained disappearance of these mature T cells occurred thereafter, leaving the scientific community grappling with the mystery of what caused their vanishing act.
The authors of the journal study noted an unusual observation: many of the patients’ neutrophils—a different type of white blood cell—displayed abnormal enlargement, engaging in substantial material consumption. This peculiar behavior, juxtaposed against an otherwise healthy profile, added another layer of complexity to the conundrum. As these interconnected puzzle pieces began to emerge, the scientific community found itself on the precipice of unraveling a broader and more intricate narrative about the role of Rac2 in immune system regulation and the perplexing dynamics within white blood cells.
Fueled by the hypothesis that patients’ T cells might be vanishing due to the predatory behavior of innate immune cells, akin to the fruit fly border cells consuming the egg chamber, Professor Montell and her team directed their focus towards macrophages—the more voracious counterparts of neutrophils. Lead author Abhinava Mishra conducted experiments wherein human macrophages with and without hyperactive Rac2 were cultured alongside T cells. The results validated their hypothesis, as macrophages with hyperactive Rac2 exhibited an increased propensity to engulf more cells, aligning with their observations in fruit flies.
To probe the connection between this heightened cellular consumption and the observed immunodeficiency, co-author Melanie Rodriguez, a graduate student in Montell’s lab, utilized bone marrow samples from mice harboring the hyperactive Rac2 mutation found in patients. Growing marrow stem cells into macrophages, Rodriguez conducted experiments similar to Mishra’s, this time co-culturing both macrophages and T cells with and without the Rac2 mutation.
The findings unveiled a complex interplay: macrophages with active Rac2 indeed consumed significantly more T cells than their normal counterparts. Intriguingly, T cells with active Rac2 also exhibited heightened vulnerability to consumption by either type of macrophage. The most plausible explanation for the observed deficiency in patients’ T cells, therefore, stemmed from a dual effect—increased consumption by macrophages coupled with heightened vulnerability of the T cells themselves.
This intricate unraveling of a medical mystery underscored the transformative potential of fundamental observations in fruit flies, illustrating the profound impact that cross-species research can have on solving pressing challenges in human medicine.
Taming unruly cells for therapeutic potential
The far-reaching implications of these discoveries unfolded in January 2020, as co-author Meghan Morrissey discussed her research during an interview for a faculty position at UCSB. In her presentation, she introduced a pioneering approach named CAR-M, where macrophages are programmed to consume cancer cells—an innovative strategy in cancer treatment. Morrissey’s work involved enhancing this behavior by incorporating a CAR receptor into macrophages.
Recognizing the potential synergy with their expertise in inducing macrophages to consume and eliminate entire living cells, Professor Montell’s lab collaborated with Morrissey, who now serves as an assistant professor of molecular, cellular, and developmental biology. The aim was to investigate whether introducing activated Rac2 could amplify the effectiveness of the CAR-M approach.
In their experiments, Rodriguez cultivated macrophages from the bone marrow of both normal and mutant mice with activated Rac2. Within each group, Morrissey expressed either a dummy receptor or the CAR receptor, which specifically targets B cells—a distinct type of white blood cell. The results were enlightening: normal and hyperactive Rac cells with dummy receptors displayed limited consumption of B cell targets. In contrast, normal macrophages equipped with CAR receptors exhibited increased consumption of B cells, consistent with Morrissey’s previous findings. However, the macrophages with both hyperactive Rac and CAR receptors demonstrated a remarkable twofold increase in the consumption of B cells compared to the CAR-only group. Activated Rac2 not only intensified the overall consumption but also seemed to elevate the number of “super eaters”—macrophages with an insatiable appetite capable of engulfing and killing multiple cancer cells simultaneously. This collaborative effort showcased the potential synergy between fundamental discoveries in cell behavior and the development of cutting-edge cancer treatment strategies, paving the way for innovative approaches in the fight against cancer.
The conclusive findings emphasized the indispensable role of both activated Rac and the receptor for achieving the heightened effect in modified macrophages. Professor Montell elucidated, stating, “If you add active Rac without the right receptor, it doesn’t do anything.” This nuanced control mechanism offers promising prospects for potential treatments, providing a means for clinicians to precisely direct the modified macrophages’ assault specifically towards cancerous cells.
The level of precision introduced by this control mechanism is particularly reassuring, mitigating concerns about the engineered cells mistakenly targeting the patient’s T-cells. Rodriguez’s previous discovery that T-cells lack the active Rac2 mutation, rendering them less susceptible to consumption by macrophages, adds an additional layer of safety to this innovative approach.
In the landscape of cancer treatments, CAR-T stands as a widely utilized strategy, leveraging the CAR receptor and a patient’s own T-cells to combat and eradicate cancers. While CAR-T has proven highly effective against certain cancers, its efficacy is not universal across all types. Enter CAR-M, a newer counterpart to CAR-T, currently undergoing clinical trials in humans and demonstrating early indications of safety. Recognizing the potential to enhance the effectiveness of CAR-M treatments, Professor Montell and her team are actively exploring the integration of Rac-enhanced CAR macrophages. The envisioned approach, aptly named Race CAR-M, holds such promise that the team has filed a provisional patent for the technique and is extending invitations to biotech companies for collaborative partnerships to advance this innovative cancer treatment strategy further. This marks a significant stride towards leveraging fundamental cellular insights for the development of advanced and targeted cancer therapies.
This comprehensive and groundbreaking paper not only delves into fundamental scientific inquiries but also presents practical implications, prompting the research lab to embark on a multifaceted exploration. The team is actively investigating the translational potential of the technique, evaluating its efficacy in freshly collected human immune cells and in animal cancer models, spanning mice and zebrafish. Simultaneously, the researchers are delving into the intricate molecular mechanisms orchestrated by Rac2 within cells to unravel the molecular underpinnings of this transformative process.
Looking ahead, Professor Montell and her team are poised to address a crucial question: the breadth of cancer types that the RaceCAR-M treatment might successfully target. Drawing a comparison to the limited scope of effectiveness exhibited by CAR-T against cancers like leukemia and lymphoma, the team is driven to explore the potential applicability of RaceCAR-M to solid-tumor cancers such as breast, lung, or colon.
The outcomes of these ongoing investigations have left Professor Montell awe-struck, marking this as her “favorite paper so far” among the extensive body of work she has contributed to the field of cell biology. Reflecting on the journey, she expressed profound satisfaction in unraveling a 25-year-old mystery in fruit flies, seamlessly connecting it to the resolution of an unexplained human immunodeficiency. This knowledge, in turn, has been harnessed to enhance the prospects of a potential cancer immunotherapy, marking a remarkable sequence of discoveries where Rac2 emerged as the pivotal solution to a series of scientific enigmas. The journey, characterized by one mystery leading to another, underscores the transformative power of persistent inquiry and the unanticipated connections that can emerge in the pursuit of scientific understanding.
Resources,
- ONLINE NEWS University of California – Santa Barbara. (2024, January 7). When bad cells go good: Harnessing cellular cannibalism for cancer treatment. Phys.org. [Phys.org]
- JOURNAL Mishra, A. K., Rodríguez, M. M. D., Torres, A. Y., Smith, M., Rodriguez, A. G., Bond, A., Morrissey, M. A., & Montell, D. J. (2023). Hyperactive Rac stimulates cannibalism of living target cells and enhances CAR-M-mediated cancer cell killing. Proceedings of the National Academy of Sciences of the United States of America, 120(52). [PNAS]
Cite this page:
APA 7: TWs Editor. (2024, January 8). Transforming Malicious Cells: Leveraging Cellular Cannibalism in the Battle Against Cancer. PerEXP Teamworks. [News Link]
